This suggests that PRF1 mediates tumor-infiltrating T lymphocytes (TIL) oligoclonal amplification-enhanced Th1 (helper T cell type I)-skewed cellular immunity during nivolumab treatment (53). The gene discussed is PRF1; the disease is neoplasm.